Canagliflozin and risk of amputation in patients with type 2 diabetes
Abstract
Sodium glucose co-transporter type 2 inhibitors (SGLT2) are a new effective group of oral hypoglygemic drugs for the treatment of diabetes type 2. At the moment there is no unanimous opinion on their safety. The article presents the data on clinical studies CANVAS and CANVAS-R and reports of the international database VigiBase (2015 - 2017) on the risk of amputation in patients with type 2 diabetes undergoing treatment with canagliflozin.
About the Authors
T. M. Bukatina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
A. S. Kazakov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
D. A. Kaperko
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
T. V. Romanova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Bundhun PK, Janoo G, Huang F. Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials. BMC Pharmacology and Toxicology 2017; 18:19.
2. Karagiannis T, Bekiari E, Tsapas A. Canagliflozin in the treatment of type 2 diabetes: an evidence- based review of its place in therapy. Core Evidence 2017; 12: 1–10.
3. Volodin AA, Maximov ML, Slobodyan VG, Alyautdin RN. SGLT2 inhibitors: control of glycemia and nephroprotection properties. Safety and risk of pharmacotherapy 2017; 5(1): 11–26 (in Russian).
4. Ushkalova EA. A new class of antidiabetic drugs—ingibitors of sodium-glucose cotransporter. Farmateka 2013; 16: 33–36 (in Russian).
5. State Register of Medicinal Products. Canagliflozin. Instructions for use. [Internet]. 2017 [cited 2017 Mar 12]. Available from: http://www.grls.rosminzdrav.ru/grls.aspx/(in Russian).
6. Messana JA, Schwartz SS, Townsend RR. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes. Vascular Health and Risk Management 2017; 13: 43–54.
7. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J. 2013; 166(2):217–223.
8. Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS- R): A randomized, placebo-controlled trial. Diabetes Obes Metab. 2017 Mar; 19(3): 387–393.
9. Mironov AN, Sakaeva IV, Matyushin AA, Shprakh ZS, Kosareva TV. Drug regulatory system in Europe. Scientific center for expertise of medical application products bulletin 2013; 2: 24–27 (in Russian).
10. PRAC concludes that diabetes medicine canagliflozin may contribute to risk of toe amputation [Internet]. Available at: http://www.ema.europa.eu/ema/.
11. SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information [Internet]. Available at: http://www.ema.europa.eu/ema/.
12. Romanov BK, Glagolev SV, Polivanov VA, Leonova MV. Monitoring of drug safety. Safety and Risk of Pharmacotherapy 2014; 3: 11–14 (in Russian).
13. Merkulov VA, Bunyatyan ND, Sakaeva IV, Lepakhin VK, Romanov BK. New legislative initiatives for improving the safety of medicines in the European Union. Scientific center for expertise of medical application products bulletin 2013; 3: 45–48 (in Russian).
Review
For citations:
Bukatina T.M., Kazakov A.S., Kaperko D.A., Romanova T.V. Canagliflozin and risk of amputation in patients with type 2 diabetes. Safety and Risk of Pharmacotherapy. 2017;5(3):100-103. (In Russ.)
Views:
1135
Email this article 